Inventiva announced that its Board of Directors called the second tranche of its previously announced structured financing, securing €115.6 million in gross proceeds, or €108.5 million net. This T2 Transaction is a crucial part of the total financing of up to €348 million.
The company confirmed that all conditions for the issuance of this second tranche have been satisfied, including the completion of patient enrollment in the NATiV3 Phase 3 clinical trial by April 30, 2025, and a study discontinuation rate below 30% prior to week 72. The net proceeds will primarily finance the ongoing NATiV3 trial and lanifibranor's development in MASH.
With the closing of the T2 Transaction, expected around May 7, 2025, and the anticipated receipt of a $10 million milestone payment from CTTQ, Inventiva estimates its cash and cash equivalents will be sufficient to fund operations until the end of the third quarter of 2026. This significantly strengthens the company's financial visibility as it progresses towards potential regulatory approval and commercialization of lanifibranor.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.